1. Home
  2. Live Updates
  3. Christie ballantyne

Live Breaking News & Updates on Christie ballantyne

Stay informed with the latest breaking news from Christie ballantyne on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Christie ballantyne and stay connected to the pulse of your community

LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

The novel agent has shown no immunogenicity issues thus far and might be a promising new PCSK9 inhibitor option.

Baylor-college-of-medicine , Texas , United-states , Johannesburg , Gauteng , South-africa , Houston , Eric-klug , Christie-ballantyne , Md-baylor-college-of-medicine , Pfizer , American-college-of-cardiology

Apolipoprotein A1 Infusions After Acute MI Disappoint in Phase III Trial

HDL therapeutic failed to reduce risk of MI, stroke, or cardiovascular death in high-risk group

Baylor-college-of-medicine , Texas , United-states , Boston , Massachusetts , Houston , Fort-pierce , Florida , Christie-ballantyne , Ed-susman , Vijay-nambi , C-michael-gibson

Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level

This suggests a broader swath of patients could be included in Lp(a)-lowering studies and potentially benefit from these agents.

Houston , Texas , United-states , Boston , Massachusetts , Baylor-college-of-medicine , Pradeep-natarajan , Christie-ballantyne , Md-baylor-college-of-medicine , Massachusetts-general-hospital , Baylor-college , Not-dependent

Johns Hopkins Bloomberg School Researchers Develop Universal Risk Predictor for Cardiovascular Disease

Universal risk predictor for cardiovascular disease, suitable for use in both primary and secondary prevention, would streamline risk assessment 

Lena-mathews , Wayne-rosamond , Michael-blaha , Christie-ballantyne , Zeina-dardari , Ron-hoogeveen , Silvia-koton , Yejin-mok , Kunihiro-matsushita , Josef-coresh , Michael-bancks , Journal-of-the-american-college-cardiology

Universal risk predictor for cardiovascular disease

Developed by Bloomberg School researchers, the model could change how doctors worldwide assess patients' chances for heart attacks, strokes, and other cardiac events

Jonathan-eichberger , Zeina-dardari , Kunihiro-matsushita , Michael-blaha , Kris-henry , Lena-mathews , Josef-coresh , Ron-hoogeveen , Wayne-rosamond , Christie-ballantyne , Yejin-mok , Silvia-koton

Johns Hopkins Bloomberg School Researchers Develop Universal Risk Predictor for Cardiovascular Disease

Researchers from the Johns Hopkins Bloomberg School of Public Health have developed a single “universal risk prediction model” for cardiovascular disease th

Christie-ballantyne , Kunihiro-matsushita , Yejin-mok , Lena-mathews , Wayne-rosamond , Zeina-dardari , Josef-coresh , Michael-bancks , Michael-blaha , Silvia-koton , Ron-hoogeveen , Wendy

Johns Hopkins Bloomberg School Researchers Develop Universal Risk Predictor for Cardiovascular Disease

Johns Hopkins Bloomberg School Researchers Develop Universal Risk Predictor for Cardiovascular Disease
newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.

Lena-mathews , Yejin-mok , Michael-bancks , Josef-coresh , Ron-hoogeveen , Silvia-koton , Michael-blaha , Kunihiro-matsushita , Christie-ballantyne , Wayne-rosamond , Zeina-dardari , Wendy

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

While there was less MACE with inclisiran, only future outcome trials will determine the drug’s ability to reduce CVD events.

Baylor-college-of-medicine , Texas , United-states , Houston , Carl-orringer , Leandro-slipczuk , Abdul-mannan-khan-minhas , R-scott-wright , Christie-ballantyne , Sanofi-regeneron , Alirocumab-praluent , Drug-administration

Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT

The weight loss drug showed a consistent reduction in major cardiovascular events over a 3-year follow up in patients with a history of heart disease who were overweight or obese.

Connecticut , United-states , University-of-texas-southwestern-medical-center , Texas , Baylor-college-of-medicine , New-york , New-haven , Philadelphia , Pennsylvania , Dallas , Boston , Massachusetts

LDL-C and Cardiovascular Disease Risk

Expert cardiologists discuss the various lines of evidence that have shown a causative effect of LDL-C in the development of atherosclerosis.

Colorado , United-states , Texas , New-orleans , Louisiana , Houston , Keithc-ferdinand , Erin-michos , Mary-mcgowan , Christie-ballantyne , Christiem-ballantyne , Geralds-berenson